180.36MMarket Cap
LossP/E TTM
Precision BioSciences Inc
Key Figures
7.080Open
7.210High
211.11KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.82%Turnover Ratio
7.000Prev. Close
6.760Low
1.10MTurnover
25.17P/E Static
2.37P/B
0.00%Div Yield TTM
-33.16%ROA
8.82052wk High
0.90Volume Ratio
7.17MNet Profit
25.81MShares
-2.1003EPS TTM
1.31Beta
-70.93%ROE
3.53052wk Low
6.43%Amplitude
100.00%Gross Margin
180.36MMarket Cap
-3.51Reward/Risk
4.29%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Precision BioSciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 38 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 29.60.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precision BioSciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Precision BioSciences Inc Highlights
StrengthsRisks
Precision BioSciences Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Precision BioSciences Inc
DTIL
5
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Precision BioSciences Inc Info
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Ticker SymbolDTIL
CompanyPrecision BioSciences Inc
CEOAmoroso (Michael)
Websitehttps://precisionbiosciences.com/
Shareholders
FAQs
What is the current price of Precision BioSciences Inc (DTIL)?
The current price of Precision BioSciences Inc (DTIL) is 6.99.
What is the symbol of Precision BioSciences Inc?
The ticker symbol of Precision BioSciences Inc is DTIL.
What is the 52-week high of Precision BioSciences Inc?
The 52-week high of Precision BioSciences Inc is 8.82.
What is the 52-week low of Precision BioSciences Inc?
The 52-week low of Precision BioSciences Inc is 3.53.
What is the market capitalization of Precision BioSciences Inc?
The market capitalization of Precision BioSciences Inc is 180.38M.
Is Precision BioSciences Inc (DTIL) currently rated as Buy, Hold, or Sell?
According to analysts, Precision BioSciences Inc (DTIL) has an overall rating of STRONG BUY, with a price target of 29.60.
What is the Earnings Per Share (EPS TTM) of Precision BioSciences Inc (DTIL)?
The Earnings Per Share (EPS TTM) of Precision BioSciences Inc (DTIL) is -3.56.
